In his weekly clinical update Dr. Griffin discusses the four things to know about RSV, the burden of respiratory syncytial virus in healthy term-born infants in Europe, the diagnostic accuracy of rapid diagnostic tests for Ebola virus disease, evaluating the accuracy of self-collected swabs for the diagnosis of monkeypox, tecovirimat is effective against human monkeypox virus in vitro at nanomolar concentrations, acute and postacute sequelae associated with SARS-CoV-2 reinfection, clinical course of SARS-CoV-2 infection and recovery in lung transplant recipients, effectiveness of a third BNT162b2 mRNA COVID-19 vaccination during pregnancy, maternal antibody response and transplacental transfer following SARS-CoV-2 infection or vaccination in pregnancy, impact of community masking on COVID-19, Lifting Universal Masking in Schools – Covid-19 Incidence among Students and Staff, systematic review of the clinical effectiveness of Tixagevimab/Cilgavimab for prophylaxis of COVID-19 in immunocompromised patients, comparative effectiveness of sotrovimab and molnupiravir for prevention of severe COVID-19 outcomes in patients in the community, early adoption of anti–SARS-CoV-2 pharmacotherapies among us veterans with mild to moderate COVID-19, evaluation of viral and symptom rebound differences between Paxlovid and untreated COVID-19 participants, monoclonal antibodies for treatment of SARS-CoV-2 infection during pregnancy, twice daily oral zinc in the treatment of patients with COVID-19, cognitive deficits in long Covid-19, severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration, and long-lasting symptoms after an acute COVID-19 infection and factors associated with their resolution.
Click arrow to play
Download TWiV 955 (28 MB .mp3, 47 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- Four things to know about RSV (Gates Foundation) 3:28
- The burden of RSV in healthy term-born infants in Europe (The Lancet) 5:25
- Diagnostic accuracy of rapid tests for Ebola (CMI) 7:32
- Accuracy of self-collected swabs for diagnosis of Monkeypox (CID) 8:16
- Tecovirimat is effective against human monkeypox virus in vitro (Nature)
- Acute and postacute sequelae associated with SARS-CoV-2 reinfection (Nature Medicine) 9:06
- SARS-CoV-2 infection and recovery in lung transplant recipients (Transplant Infectious Diseases) 14:49
- Effectiveness of third COVID-19 vaccination during pregnancy (Nature Communications) 16:23
- Maternal antibody response and transplacental transfer following infection or vaccination (CID) 17:45
- Impact of community masking on COVID-19 (Science)
- Lifting universal masking in schools (NEJM) 20:08
- Bebtelovimab fact sheet for providers (FDA)
- Effectiveness of Tixagevimab/Cilgavimab for prophylaxis of COVID-19 (medRxiv) 25:39
- Effectiveness of Sotrovimab and Molnupiravir for prevention of severe COVID-19 outcomes (BMJ) 26:34
- Early adoption of Anti–SARS-CoV-2 pharmacotherapies among US veterans (JAMA) 28:17
- PAXLOVID patient eligibility screening checklist (FDA)
- Viral and symptom rebound differences between Paxlovid and untreated COVID-19 participants (medRxiv) 30:18
- Monoclonal antibodies for treatment of SARS-CoV-2 during pregnancy (Annals of Internal Medicine) 34:47
- Remdesivir fact sheet for providers (Veklury)
- Twice daily oral zinc in the treatment of patients with COVID-19 (CID) 35:45
- Cognitive deficits in long COVID-19 (NEJM) 37:58
- Severe Neuro-COVID associated with peripheral immune signatures, autoimmunity and neurodegeneration (Nature Communications) 40:15
- Long-lasting symptoms after an acute COVID-19 Infection (JAMA) 40:50
- Contribute to our MicrobeTV fundraiser at PWB 41:34
- Dr. Griffin’s treatment guide (pdf)
- Letters read on TWiV 955 41:59
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
with regard to the letter from Susan from London, Ontario:
For a short time the Moderna bivalent vaccine approved in Canada was for wild type and omicron BA.1. This was at the same time as the bivalent BA.4/5 Pfizer vaccine was out and the BA4/5 Moderna vaccine was first available in the US. Shortly after the newer Moderna vaccine with BA4/5 was approved and became available in Canada. Why Moderna sought approval of the BA.1 vaccine and why Health Canada approved it when the BA.4/5 vaccine was imminent is rather a mystery.
Would it make sense to follow on the microglia discussion by having Jarred Younger on Immune?